Carisma Therapeutics (NASDAQ:CARM) is a biotechnology company dedicated to the discovery and development of innovative therapies. With a focus on engineered macrophage-based treatments, Carisma is at the forefront of initiating groundbreaking approaches to combat cancer and other critical illnesses. The company's operations span from research and development in cell therapy platforms to advancing clinical studies aimed at unlocking new treatment pathways. By leveraging its unique CAR-Macrophage platform, Carisma aims to harness the power of the immune system, offering new hope for patients through targeted, immune-based therapies. The company's primary objective is to deliver transformative treatments that can significantly improve patient outcomes, steering the future of immunotherapy towards more effective and less invasive options.